180 Life Sciences Corp (NASDAQ: ATNF) has offered follow-up information regarding the top-line data from Oxford University and Its Phase 2b clinical study for Dupuytren’s Disease released at the start of December 2021.
Adalimumab evaluation on Dupuytren’s yielded positive results
CEO Dr. James Woody said, “We believe the Phase 2b clinical trial for Dupuytren’s disease using adalimumab was a phenomenal achievement, having met both primary and secondary endpoints by significantly diminishing the hardness and size of the Dupuytren’s nodules, respectively. We believe these results affirm our team’s scientific and clinical expertise and fundamentally position us to be a major leader in fibrosis therapies.”
The primary and secondary study endpoints for patients with early-stage Dupuytren’s were both statistically significant in the Phase 2b clinical study. Furthermore, patients enrolled in the clinical trial had a good degree of compliance, with the majority returning for all injections, and there were no significant side events reported. This encouraging conclusion allows the company to progress to the possible commercialization of a therapeutic for a potentially unmet medical where there is no approved treatment.
Study findings to be published in a peer-reviewed journal
Unfortunately, 180 Life Sciences is unable to provide the whole data set with information that it believes would provide greater clarity surrounding the results due to the rigorous disclosure standards of prominent clinical publications, which only allow restricted data to be announced at closed scientific meetings. Surprisingly any additional clinical data revelations could disqualify the study from publication, which is something the company wants to avoid.
Although publication in a peer-reviewed journal may take several months due to the peer review process’s many different types of questions and clarifications, publishing the data in a peer-reviewed journal will offer considerable credibility to the study and represent significant progress in the Dupuytren’s disease field. Already, Professor Nanchahal has submitted his paper to a prestigious medical journal.
180 Life Sciences is in a better position with a chance to leverage the study results and advance the work of bringing a safe and effective drug to an unmet need market.
